NCT04230668

Brief Summary

Posttraumatic Stress Disorder (PTSD) with co-occurring Borderline Personality Disorder (BPD) (i.e., PTSD-BPD) is common (as high as 58%), debilitating, costly, and limited treatment options available for this population. PTSD-BPD is associated with even greater functional impairment and higher healthcare burden than either disorder alone. There are surprisingly few treatments available for this clinical profile, despite its association with major negative health outcomes, cost, and morbidity. There is a pressing need to innovate treatments that can effectively and efficiently treat PTSD-BPD. The existing treatments used for PTSD-BPD are lengthy, laborious, resource-intensive, and require complete cessation of suicidal behaviors prior to treatment. Furthermore, no integrated treatment has been innovated to deliver the active ingredients to efficiently affect the mechanisms underpinning this comorbidity. The investigators propose to examine an adapted version of a first-line PTSD intervention, Cognitive Processing Therapy, augmented with a Suicide Risk Management, i.e., (CPT+SRM) as a brief (12 sessions) and more parsimonious treatment alternative that strategically targets shared mechanisms underpinning PTSD and BPD. The purpose of this pilot study is to 1) collect initial feasibility, acceptability, and safety data on this adapted treatment, 2) conduct a pilot randomized clinical trial evaluating the efficacy of CPT+SRM versus Treatment as Usual (TAU) + SRM, and 3) evaluate two targets (i.e, improvements in emotional intensity and cognitive dysfunction) as mechanisms leading to change in our primary outcomes. Both treatment conditions will be administered via telehealth. Potential benefits include reduction in participants' PTSD, BPD and other mental health symptoms. Additionally, this work could benefit the community by improving the treatment repertoire for PTSD-BPD. Potential risks include emotional distress, suicidality, and/or self-harm. Participants may experience discomfort and/or distress while discussing participants trauma(s) and mental health. These risks will be mitigated using a suicide risk management protocol which therapists in the assessment of risk and protective factors of suicide, followed by documentation for the decision-making around the management of risk.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
33

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 9, 2020

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 18, 2020

Completed
2.7 years until next milestone

Study Start

First participant enrolled

October 1, 2022

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2025

Completed
Last Updated

January 17, 2024

Status Verified

January 1, 2024

Enrollment Period

2.3 years

First QC Date

January 9, 2020

Last Update Submit

January 12, 2024

Conditions

Keywords

Cognitive Processing TherapySuicide Risk ManagementSuicideSelf-harm

Outcome Measures

Primary Outcomes (2)

  • Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    A 30-item clinician administered structured interview based on the DSM-5 PTSD criteria.

    Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up

  • Borderline Symptom List 23 (BSL-23) [SELF-REPORT]

    A self-report measure of borderline personality disorder (BPD) severity. The measure captures subjective ratings of the following symptoms: self-perception, affect regulation, self destruction, dysphoria, loneliness, intrusions, and hostility (Bohus et al., 2009).

    Baseline, once a week while in treatment (for 6 weeks)

Secondary Outcomes (27)

  • Suicide Attempt Self-Injury Interview (SASII)

    3-weeks, Post-treatment/6-weeks, 3-month follow-up

  • Difficulties in Emotion Regulation Scale (DERS) [SELF-REPORT]

    Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up

  • Posttraumatic Cognitions Inventory (PTCI) [SELF-REPORT]

    Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up

  • Beck's Depression Inventory-II (BDI-II) [SELF-REPORT]

    Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up

  • State-Trait Anxiety Inventory, Trait Version (STAI-T)

    Baseline, 3-weeks, Post-treatment/6-weeks, 3-months follow-up

  • +22 more secondary outcomes

Study Arms (2)

CPT + SRM

EXPERIMENTAL

Participants will be randomized to teletherapy sessions of Cognitive Processing Therapy + Suicide Risk Management for PTSD-BPD which will be administered twice weekly over 6 weeks, for a total of 12 sessions.

Behavioral: Cognitive Processing Therapy with Suicide Risk Management

TAU + SRM

EXPERIMENTAL

Participants will be randomized to teletherapy sessions with only Suicide Risk Management for PTSD-BPD which will be administered once a week for 6 weeks, for a total of 6 sessions.

Behavioral: Treatment as Usual with Suicide Rick Management

Interventions

CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.

CPT + SRM

In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.

TAU + SRM

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18-65 years
  • Must reside in the Bay Area, CA
  • Current DSM-5 diagnosis of PTSD and BPD
  • Must be willing to be audio- or videorecorded for assessment and treatment sessions

You may not qualify if:

  • Acute mania, acute psychosis, or intellectual disability
  • Conditions requiring medical attention to a potentially life-threatening illness (e.g., severe anorexia nervosa)
  • Severe impairments in written and aural comprehension
  • EU individuals

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Palo Alto University

Palo Alto, California, 94304, United States

RECRUITING

Related Publications (2)

  • Resick, P. A., Monson, C. M., & Chard, K. M. (2016). Cognitive processing therapy for PTSD: A comprehensive manual. New York, NY: Guilford Press.

    BACKGROUND
  • Stanley, B., & Brown, G. (2012). Safety planning intervention: A brief intervention to mitigate suicide risk. Cognitive and Behavioural Practice, 19(2), 256-264.

    BACKGROUND

MeSH Terms

Conditions

Stress Disorders, Post-TraumaticBorderline Personality DisorderSuicideSelf-Injurious Behavior

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental DisordersPersonality DisordersBehavioral SymptomsBehavior

Study Officials

  • Janice R Kuo, PhD

    Palo Alto University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ariana Guenther, B.A.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a two-phased study. Phase 1 of this investigation will consist of an initial case series in which the CPT+SRM manual will be developed along with fidelity measures. The finalized treatment manual will then be tested in Phase 2, a randomized-controlled trial comparing 12 individual sessions/6 weeks of CPT+SRM versus 6 weeks of TAU+SRM.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 9, 2020

First Posted

January 18, 2020

Study Start

October 1, 2022

Primary Completion

December 31, 2024

Study Completion

January 31, 2025

Last Updated

January 17, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations